- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00550836
Erlotinib and Gemcitabine With or Without Panitumumab in Treating Patients With Metastatic Pancreatic Cancer
Randomized Phase II Trial of Panitumumab, Erlotinib and Gemcitabine vs. Erlotinib and Gemcitabine in Patients With Untreated, Metastatic Pancreatic Adenocarcinoma
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Panitumumab may also stop the growth of pancreatic cancer by blocking blood flow to the tumor.
PURPOSE: This randomized phase II trial is studying how well giving panitumumab together with gemcitabine and erlotinib works compared to giving gemcitabine and erlotinib alone in treating patients with metastatic pancreatic cancer.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
OBJECTIVES:
Primary
- To assess whether the addition of panitumumab (a dual-epidermal growth factor receptor inhibitor) to standard chemotherapy comprising gemcitabine hydrochloride and erlotinib hydrochloride results in an improvement in overall survival of patients with previously untreated, metastatic adenocarcinoma of the pancreas.
Secondary
- To compare objective response rates, progression-free survival, time to treatment failure, quality of life, and adverse event rates in patients treated with these regimens.
- To evaluate the downstream marker, KRAS, in stool specimens.
OUTLINE: This is a multicenter study. Patients are stratified according to ECOG performance status (0 vs 1) and prior adjuvant chemotherapy (yes vs no). The first 6 patients are assigned to arm II. Subsequent patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 and oral erlotinib hydrochloride once daily on days 1-28. Treatment repeats every 28 days for 2 courses. Patients achieving a complete response (CR) after 2 courses receive 2 additional courses of treatment; patients achieving a partial response (PR) receive retreatment as above in the absence of disease progression or unacceptable toxicity. Patients achieving a CR after 4 courses of treatment receive maintenance therapy comprising erlotinib hydrochloride daily until the first disease progression. After the first progression, patients are retreated with gemcitabine hydrochloride and erlotinib hydrochloride until second progression (using the first progression tumor measurements as the new baseline reference).
- Arm II: Patients receive gemcitabine hydrochloride and erlotinib hydrochloride as in arm I and panitumumab IV over 1 hour on days 1 and 15. Treatment repeats every 28 days for 2 courses. Patients achieving a CR after 2 courses receive 2 additional courses of treatment; patients achieving a PR receive retreatment as above in the absence of disease progression or unacceptable toxicity. Patients achieving a CR after 4 courses of treatment receive maintenance therapy comprising erlotinib hydrochloride daily and panitumumab every 2 weeks until the first disease progression. After the first progression, patients are retreated with gemcitabine hydrochloride, erlotinib hydrochloride, and panitumumab until second progression (using the first progression tumor measurements as the new baseline reference).
Stool samples are collected at baseline and analyzed for KRAS mutations via protein analyses.
Quality of life will be assessed at baseline, every 2 courses during treatment, and at the end of treatment.
After the second progression, patients are followed every 3-6 months for 2 years.
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
Colorado
-
Aurora, Colorado, Forente stater, 80012
- Aurora Presbyterian Hospital
-
Boulder, Colorado, Forente stater, 80301-9019
- Boulder Community Hospital
-
Colorado Springs, Colorado, Forente stater, 80933
- Penrose Cancer Center at Penrose Hospital
-
Denver, Colorado, Forente stater, 80210
- Porter Adventist Hospital
-
Denver, Colorado, Forente stater, 80220
- Rose Medical Center
-
Denver, Colorado, Forente stater, 80218
- Presbyterian - St. Luke's Medical Center
-
Denver, Colorado, Forente stater, 80204
- St. Anthony Central Hospital
-
Denver, Colorado, Forente stater, 80218
- St. Joseph Hospital
-
Denver, Colorado, Forente stater, 80224-2522
- CCOP - Colorado Cancer Research Program
-
Englewood, Colorado, Forente stater, 80110
- Swedish Medical Center
-
Fort Collins, Colorado, Forente stater, 80528
- Front Range Cancer Specialists
-
Grand Junction, Colorado, Forente stater, 81502
- St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center
-
Greeley, Colorado, Forente stater, 80631
- North Colorado Medical Center
-
Lone Tree, Colorado, Forente stater, 80124
- Sky Ridge Medical Center
-
Longmont, Colorado, Forente stater, 80501
- Hope Cancer Care Center at Longmont United Hospital
-
Loveland, Colorado, Forente stater, 80539
- McKee Medical Center
-
Thornton, Colorado, Forente stater, 80229
- North Suburban Medical Center
-
Wheat Ridge, Colorado, Forente stater, 80033
- Exempla Lutheran Medical Center
-
-
Connecticut
-
Hartford, Connecticut, Forente stater, 06105
- Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
-
-
Florida
-
Jacksonville, Florida, Forente stater, 32224
- Mayo Clinic - Jacksonville
-
-
Hawaii
-
Aiea, Hawaii, Forente stater, 96701
- Kapiolani Medical Center at Pali Momi
-
Honolulu, Hawaii, Forente stater, 96813
- Cancer Research Center of Hawaii
-
Honolulu, Hawaii, Forente stater, 96826
- Kapiolani Medical Center for Women and Children
-
Honolulu, Hawaii, Forente stater, 96813
- OnCare Hawaii, Incorporated - Lusitana
-
Honolulu, Hawaii, Forente stater, 96813
- Queen's Cancer Institute at Queen's Medical Center
-
Honolulu, Hawaii, Forente stater, 96813
- Straub Clinic and Hospital, Incorporated
-
Honolulu, Hawaii, Forente stater, 96817
- Hawaii Medical Center - East
-
Honolulu, Hawaii, Forente stater, 96817
- OnCare Hawaii, Incorporated - Kuakini
-
Wailuku, Hawaii, Forente stater, 96793
- Pacific Cancer Institute - Maui
-
-
Illinois
-
Bloomington, Illinois, Forente stater, 61701
- St. Joseph Medical Center
-
Bloomington%, Illinois, Forente stater, 61701
- Illinois CancerCare - Bloomington
-
Canton, Illinois, Forente stater, 61520
- Illinois CancerCare - Canton
-
Canton, Illinois, Forente stater, 61520
- Graham Hospital
-
Carthage, Illinois, Forente stater, 62321
- Memorial Hospital
-
Carthage, Illinois, Forente stater, 62321
- Illinois CancerCare - Carthage
-
Eureka, Illinois, Forente stater, 61530
- Illinois CancerCare - Eureka
-
Eureka, Illinois, Forente stater, 61530
- Eureka Community Hospital
-
Galesburg, Illinois, Forente stater, 61401
- Illinois CancerCare - Galesburg
-
Galesburg, Illinois, Forente stater, 61401
- Galesburg Clinic, PC
-
Havana, Illinois, Forente stater, 62644
- Mason District Hospital
-
Havana, Illinois, Forente stater, 62644
- Illinois CancerCare - Havana
-
Kewanee, Illinois, Forente stater, 61443
- Illinois CancerCare - Kewanee Clinic
-
Macomb, Illinois, Forente stater, 61455
- Illinois CancerCare - Macomb
-
Macomb, Illinois, Forente stater, 61455
- Mcdonough District Hospital
-
Moline, Illinois, Forente stater, 61265
-
Moline, Illinois, Forente stater, 61265
- Trinity Cancer Center at Trinity Medical Center - 7th Street Campus
-
Monmouth, Illinois, Forente stater, 61462
- Illinois CancerCare - Monmouth
-
Normal, Illinois, Forente stater, 61761
- Bromenn Regional Medical Center
-
Normal, Illinois, Forente stater, 61761
- Community Cancer Center
-
Normal, Illinois, Forente stater, 61761
- Illinois CancerCare - Community Cancer Center
-
Ottawa, Illinois, Forente stater, 61350
- Community Hospital of Ottawa
-
Ottawa, Illinois, Forente stater, 61350
- Oncology Hematology Associates of Central Illinois, PC - Ottawa
-
Pekin, Illinois, Forente stater, 61554
- Cancer Treatment Center at Pekin Hospital
-
Pekin, Illinois, Forente stater, 61603
- Illinois CancerCare - Pekin
-
Peoria, Illinois, Forente stater, 61636
- Methodist Medical Center of Illinois
-
Peoria, Illinois, Forente stater, 61614
- Proctor Hospital
-
Peoria, Illinois, Forente stater, 61637
- OSF St. Francis Medical Center
-
Peoria, Illinois, Forente stater, 61615
- CCOP - Illinois Oncology Research Association
-
Peoria, Illinois, Forente stater, 61615
- Oncology Hematology Associates of Central Illinois, PC - Peoria
-
Peru, Illinois, Forente stater, 61354
- Illinois CancerCare - Peru
-
Peru, Illinois, Forente stater, 61354
- Illinois Valley Community Hospital
-
Princeton, Illinois, Forente stater, 61356
- Perry Memorial Hospital
-
Princeton, Illinois, Forente stater, 61356
- Illinois CancerCare - Princeton
-
Spring Valley, Illinois, Forente stater, 61362
- Illinois CancerCare - Spring Valley
-
-
Indiana
-
Beech Grove, Indiana, Forente stater, 46107
- St. Francis Hospital and Health Centers - Beech Grove Campus
-
Elkhart, Indiana, Forente stater, 46515
- Elkhart General Hospital
-
Elkhart, Indiana, Forente stater, 46514-2098
- Elkhart Clinic, LLC
-
Kokomo, Indiana, Forente stater, 46904
- Howard Community Hospital
-
La Porte, Indiana, Forente stater, 46350
- Center for Cancer Therapy at LaPorte Hospital and Health Services
-
Richmond, Indiana, Forente stater, 47374
- Reid Hospital & Health Care Services
-
South Bend, Indiana, Forente stater, 46601
- Memorial Hospital of South Bend
-
South Bend, Indiana, Forente stater, 46601
- CCOP - Northern Indiana CR Consortium
-
South Bend, Indiana, Forente stater, 46617
- Saint Joseph Regional Medical Center
-
South Bend, Indiana, Forente stater, 46617
- South Bend Clinic
-
South Bend, Indiana, Forente stater, 46601
- Michiana Hematology-Oncology, PC - South Bend
-
-
Iowa
-
Ames, Iowa, Forente stater, 50010
- McFarland Clinic, PC
-
Bettendorf, Iowa, Forente stater, 52722
-
Cedar Rapids, Iowa, Forente stater, 52403
- Cedar Rapids Oncology Associates
-
Cedar Rapids, Iowa, Forente stater, 52403
- Mercy Regional Cancer Center at Mercy Medical Center
-
Clive, Iowa, Forente stater, 50325
- Medical Oncology and Hematology Associates - West Des Moines
-
Des Moines, Iowa, Forente stater, 50309
- CCOP - Iowa Oncology Research Association
-
Des Moines, Iowa, Forente stater, 50309
- John Stoddard Cancer Center at Iowa Methodist Medical Center
-
Des Moines, Iowa, Forente stater, 50309
- Medical Oncology and Hematology Associates at John Stoddard Cancer Center
-
Des Moines, Iowa, Forente stater, 50314
- Medical Oncology and Hematology Associates at Mercy Cancer Center
-
Des Moines, Iowa, Forente stater, 50314
- Mercy Cancer Center at Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Forente stater, 50316
- John Stoddard Cancer Center at Iowa Lutheran Hospital
-
Des Moines, Iowa, Forente stater, 50307
- Mercy Capitol Hospital
-
Sioux City, Iowa, Forente stater, 51101
- Siouxland Hematology-Oncology Associates, LLP
-
Sioux City, Iowa, Forente stater, 51104
- St. Luke's Regional Medical Center
-
Sioux City, Iowa, Forente stater, 51104
- Mercy Medical Center - Sioux City
-
-
Kansas
-
Chanute, Kansas, Forente stater, 66720
- Cancer Center of Kansas, PA - Chanute
-
Dodge City, Kansas, Forente stater, 67801
- Cancer Center of Kansas, PA - Dodge City
-
El Dorado, Kansas, Forente stater, 67042
- Cancer Center of Kansas, PA - El Dorado
-
Fort Scott, Kansas, Forente stater, 66701
- Cancer Center of Kansas - Fort Scott
-
Independence, Kansas, Forente stater, 67301
- Cancer Center of Kansas-Independence
-
Kingman, Kansas, Forente stater, 67068
- Cancer Center of Kansas, PA - Kingman
-
Lawrence, Kansas, Forente stater, 66044
- Lawrence Memorial Hospital
-
Liberal, Kansas, Forente stater, 67905
- Cancer Center of Kansas, PA - Liberal
-
Newton, Kansas, Forente stater, 67114
- Cancer Center of Kansas, PA - Newton
-
Parsons, Kansas, Forente stater, 67357
- Cancer Center of Kansas, PA - Parsons
-
Pratt, Kansas, Forente stater, 67124
- Cancer Center of Kansas, PA - Pratt
-
Salina, Kansas, Forente stater, 67401
- Cancer Center of Kansas, PA - Salina
-
Wellington, Kansas, Forente stater, 67152
- Cancer Center of Kansas, PA - Wellington
-
Wichita, Kansas, Forente stater, 67208
- Cancer Center of Kansas, PA - Medical Arts Tower
-
Wichita, Kansas, Forente stater, 67214
- Cancer Center of Kansas, PA - Wichita
-
Wichita, Kansas, Forente stater, 67214
- CCOP - Wichita
-
Wichita, Kansas, Forente stater, 67214
- Via Christi Cancer Center at Via Christi Regional Medical Center
-
Wichita, Kansas, Forente stater, 67208
- Associates in Womens Health, PA - North Review
-
Winfield, Kansas, Forente stater, 67156
- Cancer Center of Kansas, PA - Winfield
-
-
Louisiana
-
Baton Rouge, Louisiana, Forente stater, 70809
- Ochsner Health Center - Bluebonnet
-
Covington, Louisiana, Forente stater, 70433
- Ochsner Health Center - Covington
-
New Orleans, Louisiana, Forente stater, 70121
- CCOP - Ochsner
-
New Orleans, Louisiana, Forente stater, 70121
- Ochsner Cancer Institute at Ochsner Clinic Foundation
-
-
Michigan
-
Adrian, Michigan, Forente stater, 49221
- Hickman Cancer Center at Bixby Medical Center
-
Ann Arbor, Michigan, Forente stater, 48106-0995
- Saint Joseph Mercy Cancer Center
-
Ann Arbor, Michigan, Forente stater, 48106
- CCOP - Michigan Cancer Research Consortium
-
Dearborn, Michigan, Forente stater, 48123-2500
- Oakwood Cancer Center at Oakwood Hospital and Medical Center
-
Escanaba, Michigan, Forente stater, 49431
- Green Bay Oncology, Limited - Escanaba
-
Flint, Michigan, Forente stater, 48503
- Hurley Medical Center
-
Flint, Michigan, Forente stater, 48503
- Genesys Hurley Cancer Institute
-
Grosse Pointe Woods, Michigan, Forente stater, 48236
- Van Elslander Cancer Center at St. John Hospital and Medical Center
-
Iron Mountain, Michigan, Forente stater, 49801
- Dickinson County Healthcare System
-
Jackson, Michigan, Forente stater, 49201
- Foote Memorial Hospital
-
Lambertville, Michigan, Forente stater, 48144
- Haematology-Oncology Associates of Ohio and Michigan, PC
-
Lansing, Michigan, Forente stater, 48912-1811
- Sparrow Regional Cancer Center
-
Livonia, Michigan, Forente stater, 48154
- St. Mary Mercy Hospital
-
Monroe, Michigan, Forente stater, 48162
- Community Cancer Center of Monroe
-
Monroe, Michigan, Forente stater, 48162
- Mercy Memorial Hospital - Monroe
-
Pontiac, Michigan, Forente stater, 48341-2985
- St. Joseph Mercy Oakland
-
Port Huron, Michigan, Forente stater, 48060
- Mercy Regional Cancer Center at Mercy Hospital
-
Saginaw, Michigan, Forente stater, 48601
- Seton Cancer Institute at Saint Mary's - Saginaw
-
Saint Joseph, Michigan, Forente stater, 49085
- Lakeside Cancer Specialists, PLLC
-
St. Joseph, Michigan, Forente stater, 49085
- Lakeland Regional Cancer Care Center - St. Joseph
-
Warren, Michigan, Forente stater, 48093
- St. John Macomb Hospital
-
-
Minnesota
-
Alexandria, Minnesota, Forente stater, 56308
-
Bemidji, Minnesota, Forente stater, 56601
- MeritCare Bemidji
-
Burnsville, Minnesota, Forente stater, 55337
- Fairview Ridges Hospital
-
Coon Rapids, Minnesota, Forente stater, 55433
- Mercy and Unity Cancer Center at Mercy Hospital
-
Edina, Minnesota, Forente stater, 55435
- Fairview Southdale Hospital
-
Fergus Falls, Minnesota, Forente stater, 56537
- Fergus Falls Medical Group, PA
-
Fridley, Minnesota, Forente stater, 55432
- Mercy and Unity Cancer Center at Unity Hospital
-
Hutchinson, Minnesota, Forente stater, 55350
- Hutchinson Area Health Care
-
Maplewood, Minnesota, Forente stater, 55109
- Minnesota Oncology Hematology, PA - Maplewood
-
Maplewood, Minnesota, Forente stater, 55109
- HealthEast Cancer Care at St. John's Hospital
-
Minneapolis, Minnesota, Forente stater, 55407
- Virginia Piper Cancer Institute at Abbott - Northwestern Hospital
-
Minneapolis, Minnesota, Forente stater, 55415
- Hennepin County Medical Center - Minneapolis
-
Robbinsdale, Minnesota, Forente stater, 55422-2900
- Hubert H. Humphrey Cancer Center at North Memorial Outpatient Center
-
Rochester, Minnesota, Forente stater, 55905
- Mayo Clinic Cancer Center
-
Saint Cloud, Minnesota, Forente stater, 56303
- CentraCare Clinic - River Campus
-
Saint Cloud, Minnesota, Forente stater, 56303
- Coborn Cancer Center
-
Saint Louis Park, Minnesota, Forente stater, 55416
- CCOP - Metro-Minnesota
-
Saint Louis Park, Minnesota, Forente stater, 55416
- Park Nicollet Cancer Center
-
Saint Paul, Minnesota, Forente stater, 55102
- United Hospital
-
Shakopee, Minnesota, Forente stater, 55379
- St. Francis Cancer Center at St. Francis Medical Center
-
St. Paul, Minnesota, Forente stater, 55101
- Regions Hospital Cancer Care Center
-
Waconia, Minnesota, Forente stater, 55387
- Ridgeview Medical Center
-
Woodbury, Minnesota, Forente stater, 55125
- Minnesota Oncology Hematology, PA - Woodbury
-
-
Montana
-
Billings, Montana, Forente stater, 59101
- CCOP - Montana Cancer Consortium
-
Billings, Montana, Forente stater, 59101
- Hematology-Oncology Centers of the Northern Rockies - Billings
-
Billings, Montana, Forente stater, 59101
- Northern Rockies Radiation Oncology Center
-
Billings, Montana, Forente stater, 59101
- St. Vincent Healthcare Cancer Care Services
-
Billings, Montana, Forente stater, 59107-7000
- Billings Clinic - Downtown
-
Bozeman, Montana, Forente stater, 59715
- Bozeman Deaconess Cancer Center
-
Butte, Montana, Forente stater, 59701
- St. James Healthcare Cancer Care
-
Great Falls, Montana, Forente stater, 59405
- Great Falls Clinic - Main Facility
-
Great Falls, Montana, Forente stater, 59405
-
Great Falls, Montana, Forente stater, 59405-5309
- Big Sky Oncology
-
Great Falls, Montana, Forente stater, 59405
- Sletten Cancer Institute at Benefis Healthcare
-
Havre, Montana, Forente stater, 59501
- Northern Montana Hospital
-
Helena, Montana, Forente stater, 59601
- St. Peter's Hospital
-
Kalispell, Montana, Forente stater, 59901
- Glacier Oncology, PLLC
-
Kalispell, Montana, Forente stater, 59901
- Kalispell Medical Oncology at KRMC
-
Missoula, Montana, Forente stater, 59804
- Guardian Oncology and Center for Wellness
-
Missoula, Montana, Forente stater, 59807-7877
- Montana Cancer Specialists at Montana Cancer Center
-
Missoula, Montana, Forente stater, 59807
- Montana Cancer Center at St. Patrick Hospital and Health Sciences Center
-
-
Nebraska
-
Lincoln, Nebraska, Forente stater, 68510
- Cancer Resource Center - Lincoln
-
Omaha, Nebraska, Forente stater, 68106
- CCOP - Missouri Valley Cancer Consortium
-
Omaha, Nebraska, Forente stater, 68122
- Immanuel Medical Center
-
Omaha, Nebraska, Forente stater, 68124
- Alegant Health Cancer Center at Bergan Mercy Medical Center
-
Omaha, Nebraska, Forente stater, 68131-2197
- Creighton University Medical Center
-
-
North Carolina
-
Rutherfordton, North Carolina, Forente stater, 28139
- Rutherford Hospital
-
-
North Dakota
-
Bismarck, North Dakota, Forente stater, 58501
- Bismarck Cancer Center
-
Bismarck, North Dakota, Forente stater, 58501
- Medcenter One Hospital Cancer Care Center
-
Bismarck, North Dakota, Forente stater, 58501
- Mid Dakota Clinic, PC
-
Bismarck, North Dakota, Forente stater, 58502
- St. Alexius Medical Center Cancer Center
-
Fargo, North Dakota, Forente stater, 58122
- CCOP - MeritCare Hospital
-
Fargo, North Dakota, Forente stater, 58122
- MeritCare Broadway
-
Grand Forks, North Dakota, Forente stater, 58201
- Altru Cancer Center at Altru Hospital
-
-
Ohio
-
Bowling Green, Ohio, Forente stater, 43402
- Wood County Oncology Center
-
Clyde, Ohio, Forente stater, 43410
- North Coast Cancer Care - Clyde
-
Dayton, Ohio, Forente stater, 45405
- Grandview Hospital
-
Dayton, Ohio, Forente stater, 45406
- Good Samaritan Hospital
-
Dayton, Ohio, Forente stater, 45409
- David L. Rike Cancer Center at Miami Valley Hospital
-
Dayton, Ohio, Forente stater, 45415
- Samaritan North Cancer Care Center
-
Dayton, Ohio, Forente stater, 45420
- CCOP - Dayton
-
Elyria, Ohio, Forente stater, 44035
- Community Cancer Center
-
Elyria, Ohio, Forente stater, 44035
- Hematology Oncology Center
-
Findlay, Ohio, Forente stater, 45840
- Blanchard Valley Medical Associates
-
Franklin, Ohio, Forente stater, 45005-1066
- Middletown Regional Hospital
-
Greenville, Ohio, Forente stater, 45331
- Wayne Hospital
-
Kettering, Ohio, Forente stater, 45429
- Charles F. Kettering Memorial Hospital
-
Lima, Ohio, Forente stater, 45804
- Lima Memorial Hospital
-
Maumee, Ohio, Forente stater, 43537
- St. Luke's Hospital
-
Maumee, Ohio, Forente stater, 43537-1839
- Northwest Ohio Oncology Center
-
Norwalk, Ohio, Forente stater, 44857
- Fisher-Titus Medical Center
-
Oregon, Ohio, Forente stater, 43616
- St. Charles Mercy Hospital
-
Oregon, Ohio, Forente stater, 43616
- Toledo Clinic - Oregon
-
Sandusky, Ohio, Forente stater, 44870
- North Coast Cancer Care, Incorporated
-
Sylvania, Ohio, Forente stater, 43560
- Flower Hospital Cancer Center
-
Tiffin, Ohio, Forente stater, 44883
- Mercy Hospital of Tiffin
-
Toledo, Ohio, Forente stater, 43608
- St. Vincent Mercy Medical Center
-
Toledo, Ohio, Forente stater, 43606
- Toledo Hospital
-
Toledo, Ohio, Forente stater, 43614
- Medical University of Ohio Cancer Center
-
Toledo, Ohio, Forente stater, 43617
- CCOP - Toledo Community Hospital
-
Toledo, Ohio, Forente stater, 43623
- Toledo Clinic, Incorporated - Main Clinic
-
Toledo, Ohio, Forente stater, 43623
- St. Anne Mercy Hospital
-
Troy, Ohio, Forente stater, 45373-1300
- UVMC Cancer Care Center at Upper Valley Medical Center
-
Wauseon, Ohio, Forente stater, 43567
- Fulton County Health Center
-
Wilmington, Ohio, Forente stater, 45177
- Clinton Memorial Hospital
-
Xenia, Ohio, Forente stater, 45385
- Ruth G. McMillan Cancer Center at Greene Memorial Hospital
-
-
Oklahoma
-
Tulsa, Oklahoma, Forente stater, 74136
- Natalie Warren Bryant Cancer Center at St. Francis Hospital
-
-
Oregon
-
Milwaukie, Oregon, Forente stater, 97222
- Providence Milwaukie Hospital
-
Portland, Oregon, Forente stater, 97216
- Adventist Medical Center
-
Portland, Oregon, Forente stater, 97213-2967
- Providence Cancer Center at Providence Portland Medical Center
-
Portland, Oregon, Forente stater, 97225
- CCOP - Columbia River Oncology Program
-
Portland, Oregon, Forente stater, 97225
- Providence St. Vincent Medical Center
-
-
Pennsylvania
-
Allentown, Pennsylvania, Forente stater, 18105
- Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest
-
Danville, Pennsylvania, Forente stater, 17822-0001
- Geisinger Cancer Institute at Geisinger Health
-
Hazleton, Pennsylvania, Forente stater, 18201
- Geisinger Hazleton Cancer Center
-
Sayre, Pennsylvania, Forente stater, 18840
- Guthrie Cancer Center at Guthrie Clinic Sayre
-
State College, Pennsylvania, Forente stater, 16801
- Geisinger Medical Group - Scenery Park
-
Wilkes-Barre, Pennsylvania, Forente stater, 18711
- Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center
-
-
South Carolina
-
Anderson, South Carolina, Forente stater, 29621
- AnMed Cancer Center
-
Spartanburg, South Carolina, Forente stater, 29303
- CCOP - Upstate Carolina
-
Spartanburg, South Carolina, Forente stater, 29303
- Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
-
-
South Dakota
-
Rapid City, South Dakota, Forente stater, 57701
- Rapid City Regional Hospital
-
Sioux Falls, South Dakota, Forente stater, 57105
- Medical X-Ray Center, PC
-
Sioux Falls, South Dakota, Forente stater, 57117-5039
- Sanford Cancer Center at Sanford USD Medical Center
-
-
Virginia
-
Fredericksburg, Virginia, Forente stater, 22401
- Fredericksburg Oncology, Incorporated
-
-
Washington
-
Vancouver, Washington, Forente stater, 98668
- Southwest Washington Medical Center Cancer Center
-
-
Wisconsin
-
Chippewa Falls, Wisconsin, Forente stater, 54729
- Marshfield Clinic - Chippewa Center
-
Eau Claire, Wisconsin, Forente stater, 54701
- Marshfield Clinic Cancer Care at Regional Cancer Center
-
Eau Claire, Wisconsin, Forente stater, 54703-1510
- Midelfort Clinic - Luther
-
Eau Claire, Wisconsin, Forente stater, 54702
- Luther Midlelfort Hospital
-
Green Bay, Wisconsin, Forente stater, 54307-3508
- St. Vincent Hospital Regional Cancer Center
-
Green Bay, Wisconsin, Forente stater, 54301-3526
- Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
-
Green Bay, Wisconsin, Forente stater, 54303
- Green Bay Oncology, Limited at St. Mary's Hospital
-
Green Bay, Wisconsin, Forente stater, 54303
- St. Mary's Hospital Medical Center - Green Bay
-
Manitowoc, Wisconsin, Forente stater, 54221-1450
- Holy Family Memorial Medical Center Cancer Care Center
-
Marinette, Wisconsin, Forente stater, 54143
- Bay Area Cancer Care Center at Bay Area Medical Center
-
Marshfield, Wisconsin, Forente stater, 54449
- Marshfield Clinic - Marshfield Center
-
Minocqua, Wisconsin, Forente stater, 54548
- Marshfield Clinic - Lakeland Center
-
Oconto Falls, Wisconsin, Forente stater, 54154
- Green Bay Oncology, Limited - Oconto Falls
-
Rhinelander, Wisconsin, Forente stater, 54501
- Ministry Medical Group at Saint Mary's Hospital
-
Rice Lake, Wisconsin, Forente stater, 54868
- Marshfield Clinic - Indianhead Center
-
Stevens Point, Wisconsin, Forente stater, 54481
- Marshfield Clinic at Saint Michael's Hospital
-
Sturgeon Bay, Wisconsin, Forente stater, 54235
- Green Bay Oncology, Limited - Sturgeon Bay
-
Wausau, Wisconsin, Forente stater, 54401
- Marshfield Clinic - Wausau Center
-
Weston, Wisconsin, Forente stater, 54476
- Marshfield Clinic - Weston Center
-
Wisconsin Rapids, Wisconsin, Forente stater, 54494
- Marshfield Clinic - Wisconsin Rapids Center
-
-
Wyoming
-
Casper, Wyoming, Forente stater, 82609
- Rocky Mountain Oncology
-
Sheridan, Wyoming, Forente stater, 82801
- Welch Cancer Center at Sheridan Memorial Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed adenocarcinoma of the pancreas (ductal or undifferentiated)
- Metastatic disease
- No islet cell, acinar cell, or cystadenocarcinomas
- No locally advanced disease
- No history or known presence of CNS metastases
PATIENT CHARACTERISTICS:
- ECOG performance status 0-1
- Life expectancy ≥ 3 months
- ANC ≥ 1,500/mm^3
- Platelet count ≥ 100,000/mm^3
- Total bilirubin ≤ 2 times upper limit of normal (ULN) (patients may be stented)
- AST ≤ 2.5 times ULN
- Creatinine ≤ 2.0 times ULN
- Magnesium ≥ lower limit of normal
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- Willing to provide a stool specimen
- No malignancy diagnosed within the past 3 years except basal cell or squamous cell skin cancer, prostate cancer (Gleason < 7), or carcinoma in situ of the cervix
- No uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements
- No clinically significant cardiovascular disease (i.e., myocardial infarction, unstable angina, symptomatic congestive heart failure, or serious uncontrolled cardiac arrhythmia) within the past year
- No known positive test(s) for HIV infection, hepatitis C virus, or acute or chronic active hepatitis B infection
- No liver dysfunction from cirrhosis or viral hepatitis
- No enteral hyperalimentation
- No grapefruit or grapefruit juice during the study
PRIOR CONCURRENT THERAPY:
- Recovered from prior therapy
- More than 4 months since prior radiotherapy, immunotherapy, or biologic therapy
- More than 4 weeks since prior and no elective or planned major surgery
- More than 2 weeks since prior minor and no elective or planned surgery
No prior cytotoxic chemotherapy for metastatic disease
Adjuvant chemotherapy for completely resected disease or chemoradiotherapy for locally advanced disease is allowed, provided it was administered > 6 months prior to study entry
- Adjuvant chemotherapy must not have contained an EGFR inhibitor
- Gemcitabine hydrochloride used as either a radiosensitizer or as maintenance therapy is allowed, provided more than 6 months have elapsed since the last day of treatment
- No prior anti-EGFR antibody therapy (e.g., cetuximab) or treatment with small molecule EGFR inhibitors (e.g., gefitinib hydrochloride, erlotinib hydrochloride, or lapatinib)
- No concurrent immunotherapy or radiotherapy
- No other concurrent chemotherapy
- No concurrent colony-stimulating factors during the first course of study therapy
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: Arm A: GE
Patients receive 1000 mg/m^2 gemcitabine hydrochloride IV on days 1, 8, and 15; and 100 mg oral erlotinib hydrochloride on days 1-28.
Treatment repeats every 28 days for 2 courses.
Patients achieving a complete response (CR) after 2 courses receive 2 additional courses of treatment; patients achieving a partial response (PR) receive retreatment as above.
Patients achieving a CR after 4 courses of treatment receive erlotinib hydrochloride until the first disease progression.
After the first progression, patients are retreated with gemcitabine hydrochloride and erlotinib hydrochloride until second progression.
|
Gitt IV
Gis muntlig
|
|
Eksperimentell: Arm B: PGE
Patients receive 1000 mg/m^2 gemcitabine hydrochloride IV on days 1, 8, and 15; 100 mg oral erlotinib hydrochloride on days 1 - 28; and 4.0 mg/kg panitumumab IV on days 1 and 15.
Treatment repeats every 28 days for 2 courses.
Patients achieving a CR after 2 courses receive 2 additional courses of treatment; patients achieving a PR receive retreatment as above.
Patients achieving a CR after 4 courses of treatment receive erlotinib hydrochloride and panitumumab until the first disease progression.
After the first progression, patients are retreated with gemcitabine hydrochloride, erlotinib hydrochloride, and panitumumab until second progression.
|
Gitt IV
Gis muntlig
Gitt IV
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Overall Survival
Tidsramme: Up to 2 years
|
Overall Survival is defined as the time from registration to death due to any cause.
The estimate will be done using the Kaplan-Meier method.
The primary goal of this trial is to compare the experimental arm (Arm B) to the standard arm (Arm A).
The primary analysis will be a comparison of Arm A to Arm B using a one-sided log-rank test between the 2 Kaplan-Meier curves.
|
Up to 2 years
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Confirmed Response Rate
Tidsramme: Up to 2 years
|
Evaluated using RECIST version 1.0.
Confirmed tumor response rate was defined as achieving partial response (PR) or complete response (CR) in two consecutive assessments at least 6 weeks apart.
CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD.
The confirmed response rate is reported as the number of participants with confirmed responses divided by the number of evaluated participants.
|
Up to 2 years
|
|
Progression-free Survival
Tidsramme: Up to 2 years
|
Progression-free survival is defined as the time from randomization to documentation of disease progression or death, whichever comes first.
Progression is defined as at least a 20% increase in the sum of longest dimension (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
The distribution of progression-free survival will be estimated using the method of Kaplan-Meier.
The progression-free survival curves will be compared between the 2 arms using a log-rank test.
|
Up to 2 years
|
|
Time to Treatment Failure
Tidsramme: Up to 2 years
|
Time to treatment failure is defined to be the time from the date of randomization to the date at which the patient is removed from treatment due to progression, adverse events, or refusal.
If the patient is considered to be a major treatment violation or is taken off study as a nonprotocol failure, the patient will be censored on the date they are removed from treatment.
The time to treatment failure will be estimated using the method of Kaplan-Meier.
|
Up to 2 years
|
|
Frequency and Severity of Observed Adverse Effects
Tidsramme: Up to 2 years
|
Patients are assessed for Adverse events each cycle using the Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0). The maximum grade for each type of adverse event will be recorded for each patient, and tables will be reviewed to determine adverse event patterns. The number of patients in each arm that reported a grade 3 or higher adverse event and a grade 4 or higher adverse event are reported. A complete listing of all adverse events is reported in the Adverse Events section. |
Up to 2 years
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Etterforskere
- Studiestol: George P. Kim, MD, Mayo Clinic
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Sykdommer i fordøyelsessystemet
- Neoplasmer
- Neoplasmer etter nettsted
- Sykdommer i det endokrine systemet
- Neoplasmer i fordøyelsessystemet
- Neoplasmer i endokrine kjertel
- Pankreassykdommer
- Neoplasmer i bukspyttkjertelen
- Fysiologiske effekter av legemidler
- Molekylære mekanismer for farmakologisk virkning
- Anti-infeksjonsmidler
- Antivirale midler
- Enzymhemmere
- Antimetabolitter, antineoplastisk
- Antimetabolitter
- Antineoplastiske midler
- Immunsuppressive midler
- Immunologiske faktorer
- Antineoplastiske midler, immunologiske
- Proteinkinasehemmere
- Gemcitabin
- Erlotinib hydroklorid
- Panitumumab
Andre studie-ID-numre
- NCCTG-N064B
- NCI-2009-01089 (Registeridentifikator: CTRP (Clinical Trials Reporting System))
- CDR0000571863 (Registeridentifikator: PDQ (Physician Data Query))
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .